177Lu-ART-101 / WARF Therap, University of Wisconsin - Madison, Archeus Technologies - LARVOL DELTA

Archeus Technologies and Wisconsin Alumni Research Foundation Partner to Advance Radiopharmaceutical Therapy ART-101 into Clinical Development for Prostate Cancer (Businesswire) - "Archeus Technologies...and the Wisconsin Alumni Research Foundation (WARF), the patenting and licensing arm of the University of Wisconsin–Madison (UW), today announced a strategic collaboration to advance ART-101 – a promising receptor-based targeting molecule – into clinical development....Through a collaboration agreement with WARF, Archeus Technologies will lead Phase 1 clinical development of this asset with trial initiation planned for 2025. ART-101 is a next-generation prostate-specific membrane antigen (PSMA)-targeting small molecule. It is being evaluated as a radiopharmaceutical agent with the potential to deliver alpha-emitting isotopes with greater tolerability compared with current standards of care."

Licensing / partnership • New P1 trial • Prostate Cancer

SHINE Technologies Collaborates with University of Wisconsin-Madison and WARF Therapeutics to Create Promising New Treatments for Kidney and Prostate Cancers (PRNewswire) - "SHINE Technologies...and WARF Therapeutics...announced promising pre-clinical research results from collaborative efforts with Advanced Radiotheranostics Lab at the University of Wisconsin-Madison....The initial pre-clinical results of 177Lu-WT-7695 show unprecedently high tumor uptake at 24h and significant tumor retention at seven days. Consequently, treatment studies lead to significant tumor regression and 100% survival in a mouse model of kidney cancer. WT-7695 is a best-in-class CA9 radiopharmaceutical and is moving into IND-enabling studies in early 2025....The study showed that ART-101 demonstrated superior tumor growth inhibition compared to existing radiopharmaceuticals targeting the prostate specific membrane antigen....The group plans to have WT-7695 and ART-101 move on to human trials within the next year."

New trial • Preclinical • Kidney Cancer • Prostate Cancer • Renal Cell Carcinoma